Immunicon Inks Biomarker Assay, Lab Services Deal with Merck Serono | GenomeWeb
Immunicon this week announced that it has signed a laboratory services and biomarker assay development pact with Merck Serono, the Geneva-based unit of Germany’s Merck KGaA.
 
Under the deal, Immunicon will develop specialized biomarker assays based on circulating tumor cells for an early clinical drug study. Immunicon said the new assays could potentially help doctors identify patients who have a high probability of responding to the drug being developed by Merck Serono.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.